Tags

Type your tag names separated by a space and hit enter

Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Cancer. 1994 Mar 01; 73(5):1398-405.C

Abstract

BACKGROUND

Evidence suggests that plasminogen activators and their inhibitors play an important role in tumor spread.

METHODS

In this study, we measured the antigen levels of urokinase (u-PA), tissue plasminogen activator (t-PA), type 1 plasminogen activator inhibitor (PAI-1), and type 2 plasminogen activator inhibitor (PAI-2), and cancer tissue (19 adenocarcinomas and 19 squamous cell carcinomas) and normal lung tissue.

RESULTS

u-PA, PAI-1, and PAI-2 antigen levels in cancer tissue were significantly higher than those in normal tissue (P < 0.001 in u-PA and PAI-1; P < 0.005 in PAI-2), whereas t-PA antigen levels in cancer tissue were significantly lower than those in normal tissue (P < 0.005). In case with lymph node involvement (LN+ cases), PAI-2 antigen levels were significantly lower than those in cases without lymph node involvement (LN- cases) (P < 0.02), whereas there was no difference in either u-PA or PAI-1 antigen levels between these two groups. Furthermore, u-PA antigen levels showed a significant positive correlation with PAI-2 antigen levels in LN- cases (r = 0.696; P < 0.005), although there was no correlation between these two parameters in LN+ cases.

CONCLUSIONS

The antigen levels of u-PA, PAI-1, and PAI-2 in cancer tissue were significantly higher than those in normal tissue, and lower content of PAI-2 was associated with lymph node metastasis.

Authors+Show Affiliations

Department of Internal Medicine, Hamamatsu University, School of Medicine, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

8111706

Citation

Nagayama, M, et al. "Plasminogen Activators and Their Inhibitors in Non-small Cell Lung Cancer. Low Content of Type 2 Plasminogen Activator Inhibitor Associated With Tumor Dissemination." Cancer, vol. 73, no. 5, 1994, pp. 1398-405.
Nagayama M, Sato A, Hayakawa H, et al. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. Cancer. 1994;73(5):1398-405.
Nagayama, M., Sato, A., Hayakawa, H., Urano, T., Takada, Y., & Takada, A. (1994). Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. Cancer, 73(5), 1398-405.
Nagayama M, et al. Plasminogen Activators and Their Inhibitors in Non-small Cell Lung Cancer. Low Content of Type 2 Plasminogen Activator Inhibitor Associated With Tumor Dissemination. Cancer. 1994 Mar 1;73(5):1398-405. PubMed PMID: 8111706.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination. AU - Nagayama,M, AU - Sato,A, AU - Hayakawa,H, AU - Urano,T, AU - Takada,Y, AU - Takada,A, PY - 1994/3/1/pubmed PY - 1994/3/1/medline PY - 1994/3/1/entrez SP - 1398 EP - 405 JF - Cancer JO - Cancer VL - 73 IS - 5 N2 - BACKGROUND: Evidence suggests that plasminogen activators and their inhibitors play an important role in tumor spread. METHODS: In this study, we measured the antigen levels of urokinase (u-PA), tissue plasminogen activator (t-PA), type 1 plasminogen activator inhibitor (PAI-1), and type 2 plasminogen activator inhibitor (PAI-2), and cancer tissue (19 adenocarcinomas and 19 squamous cell carcinomas) and normal lung tissue. RESULTS: u-PA, PAI-1, and PAI-2 antigen levels in cancer tissue were significantly higher than those in normal tissue (P < 0.001 in u-PA and PAI-1; P < 0.005 in PAI-2), whereas t-PA antigen levels in cancer tissue were significantly lower than those in normal tissue (P < 0.005). In case with lymph node involvement (LN+ cases), PAI-2 antigen levels were significantly lower than those in cases without lymph node involvement (LN- cases) (P < 0.02), whereas there was no difference in either u-PA or PAI-1 antigen levels between these two groups. Furthermore, u-PA antigen levels showed a significant positive correlation with PAI-2 antigen levels in LN- cases (r = 0.696; P < 0.005), although there was no correlation between these two parameters in LN+ cases. CONCLUSIONS: The antigen levels of u-PA, PAI-1, and PAI-2 in cancer tissue were significantly higher than those in normal tissue, and lower content of PAI-2 was associated with lymph node metastasis. SN - 0008-543X UR - https://www.unboundmedicine.com/medline/citation/8111706/Plasminogen_activators_and_their_inhibitors_in_non_small_cell_lung_cancer__Low_content_of_type_2_plasminogen_activator_inhibitor_associated_with_tumor_dissemination_ L2 - http://www.diseaseinfosearch.org/result/4334 DB - PRIME DP - Unbound Medicine ER -